Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
BSTC's Cash-to-Debt is ranked higher than
99% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. BSTC: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
BSTC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.90
BSTC's Equity-to-Asset is ranked higher than
83% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. BSTC: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
BSTC' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.34  Med: 0.85 Max: 0.98
Current: 0.9
-5.34
0.98
Interest Coverage No Debt
BSTC's Interest Coverage is ranked higher than
99% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. BSTC: No Debt )
Ranked among companies with meaningful Interest Coverage only.
BSTC' s Interest Coverage Range Over the Past 10 Years
Min: 80.45  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 27.60
Beneish M-Score: -2.03
WACC vs ROIC
15.51%
128.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 62.82
BSTC's Operating Margin % is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. BSTC: 62.82 )
Ranked among companies with meaningful Operating Margin % only.
BSTC' s Operating Margin % Range Over the Past 10 Years
Min: -296.7  Med: 45.75 Max: 64.86
Current: 62.82
-296.7
64.86
Net Margin % 42.40
BSTC's Net Margin % is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. BSTC: 42.40 )
Ranked among companies with meaningful Net Margin % only.
BSTC' s Net Margin % Range Over the Past 10 Years
Min: -300.13  Med: 34.86 Max: 57.93
Current: 42.4
-300.13
57.93
ROE % 19.60
BSTC's ROE % is ranked higher than
93% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. BSTC: 19.60 )
Ranked among companies with meaningful ROE % only.
BSTC' s ROE % Range Over the Past 10 Years
Min: -31.9  Med: 20.47 Max: 61.21
Current: 19.6
-31.9
61.21
ROA % 17.16
BSTC's ROA % is ranked higher than
96% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. BSTC: 17.16 )
Ranked among companies with meaningful ROA % only.
BSTC' s ROA % Range Over the Past 10 Years
Min: -156.91  Med: 18.9 Max: 53.14
Current: 17.16
-156.91
53.14
ROC (Joel Greenblatt) % 393.45
BSTC's ROC (Joel Greenblatt) % is ranked higher than
98% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. BSTC: 393.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSTC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -406600  Med: 161.12 Max: 404.75
Current: 393.45
-406600
404.75
3-Year Revenue Growth Rate 20.00
BSTC's 3-Year Revenue Growth Rate is ranked higher than
73% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. BSTC: 20.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSTC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.8  Med: 6.75 Max: 65.2
Current: 20
-46.8
65.2
3-Year EBITDA Growth Rate 30.70
BSTC's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. BSTC: 30.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSTC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7.7 Max: 157.7
Current: 30.7
0
157.7
3-Year EPS without NRI Growth Rate 27.10
BSTC's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. BSTC: 27.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BSTC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.3  Med: 2.35 Max: 104.1
Current: 27.1
-60.3
104.1
GuruFocus has detected 1 Warning Sign with BioSpecifics Technologies Corp BSTC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSTC's 30-Y Financials

Financials (Next Earnings Date: 2018-03-15)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

BSTC Guru Trades in Q4 2016

Jim Simons 332,746 sh (+10.23%)
Chuck Royce 45,000 sh (-40.48%)
» More
Q1 2017

BSTC Guru Trades in Q1 2017

Jim Simons 352,627 sh (+5.97%)
Chuck Royce 39,400 sh (-12.44%)
» More
Q2 2017

BSTC Guru Trades in Q2 2017

Jim Simons 398,800 sh (+13.09%)
Chuck Royce 39,400 sh (unchged)
» More
Q3 2017

BSTC Guru Trades in Q3 2017

Jim Simons 415,300 sh (+4.14%)
Chuck Royce 39,517 sh (+0.30%)
» More
» Details

Insider Trades

Latest Guru Trades with BSTC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:MRTX, NAS:BLCM, NAS:GERN, ROCO:6540, LSE:FARN, NAS:CDXS, TSE:4564, NAS:OBSV, TSXV:MJN, OTCPK:AXIM, LSE:DDDD, NAS:CERS, TSE:2183, NAS:ABUS, XTER:MDG1, NAS:MRUS, XKRX:001630, NAS:EDGE, NAS:CLDX, NAS:MRSN » details
Traded in other countries:1B3.Germany,
Headquarter Location:USA
BioSpecifics Technologies Corp is a biopharmaceutical company. It is developing an injectable collagenase clostridium histolyticum for multiple indications which is marketed as XIAFLEX in the United States or Xiapex in Europe.

BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted disease are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive cabsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.

Ratios

vs
industry
vs
history
PE Ratio 27.02
BSTC's PE Ratio is ranked higher than
51% of the 247 Companies
in the Global Biotechnology industry.

( Industry Median: 29.02 vs. BSTC: 27.02 )
Ranked among companies with meaningful PE Ratio only.
BSTC' s PE Ratio Range Over the Past 10 Years
Min: 15.05  Med: 33.53 Max: 88.33
Current: 27.02
15.05
88.33
Forward PE Ratio 25.45
BSTC's Forward PE Ratio is ranked lower than
57% of the 68 Companies
in the Global Biotechnology industry.

( Industry Median: 24.21 vs. BSTC: 25.45 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 27.02
BSTC's PE Ratio without NRI is ranked higher than
52% of the 245 Companies
in the Global Biotechnology industry.

( Industry Median: 29.70 vs. BSTC: 27.02 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSTC' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.05  Med: 33.53 Max: 88.33
Current: 27.02
15.05
88.33
PB Ratio 4.75
BSTC's PB Ratio is ranked lower than
62% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. BSTC: 4.75 )
Ranked among companies with meaningful PB Ratio only.
BSTC' s PB Ratio Range Over the Past 10 Years
Min: 4.64  Med: 7.45 Max: 571.43
Current: 4.75
4.64
571.43
PS Ratio 11.48
BSTC's PS Ratio is ranked lower than
51% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. BSTC: 11.48 )
Ranked among companies with meaningful PS Ratio only.
BSTC' s PS Ratio Range Over the Past 10 Years
Min: 7.84  Med: 14.71 Max: 75.09
Current: 11.48
7.84
75.09
Price-to-Free-Cash-Flow 28.70
BSTC's Price-to-Free-Cash-Flow is ranked higher than
59% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.07 vs. BSTC: 28.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSTC' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.9  Med: 44.58 Max: 3552.86
Current: 28.7
13.9
3552.86
Price-to-Operating-Cash-Flow 28.70
BSTC's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 25.45 vs. BSTC: 28.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSTC' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 13.9  Med: 44.58 Max: 3552.86
Current: 28.7
13.9
3552.86
EV-to-EBIT 14.77
BSTC's EV-to-EBIT is ranked higher than
62% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. BSTC: 14.77 )
Ranked among companies with meaningful EV-to-EBIT only.
BSTC' s EV-to-EBIT Range Over the Past 10 Years
Min: -128.8  Med: 17.4 Max: 63.9
Current: 14.77
-128.8
63.9
EV-to-EBITDA 13.18
BSTC's EV-to-EBITDA is ranked higher than
64% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. BSTC: 13.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSTC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.2  Med: 16.6 Max: 62.9
Current: 13.18
-132.2
62.9
EV-to-Revenue 9.28
BSTC's EV-to-Revenue is ranked higher than
56% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. BSTC: 9.28 )
Ranked among companies with meaningful EV-to-Revenue only.
BSTC' s EV-to-Revenue Range Over the Past 10 Years
Min: 7  Med: 12.9 Max: 75.9
Current: 9.28
7
75.9
PEG Ratio 0.91
BSTC's PEG Ratio is ranked higher than
74% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.09 vs. BSTC: 0.91 )
Ranked among companies with meaningful PEG Ratio only.
BSTC' s PEG Ratio Range Over the Past 10 Years
Min: 0.71  Med: 0.85 Max: 1.11
Current: 0.91
0.71
1.11
Shiller PE Ratio 64.39
BSTC's Shiller PE Ratio is ranked lower than
64% of the 70 Companies
in the Global Biotechnology industry.

( Industry Median: 41.36 vs. BSTC: 64.39 )
Ranked among companies with meaningful Shiller PE Ratio only.
BSTC' s Shiller PE Ratio Range Over the Past 10 Years
Min: 63.91  Med: 131.04 Max: 1349
Current: 64.39
63.91
1349
Current Ratio 30.83
BSTC's Current Ratio is ranked higher than
95% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. BSTC: 30.83 )
Ranked among companies with meaningful Current Ratio only.
BSTC' s Current Ratio Range Over the Past 10 Years
Min: 0.43  Med: 6.77 Max: 48.18
Current: 30.83
0.43
48.18
Quick Ratio 30.83
BSTC's Quick Ratio is ranked higher than
95% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. BSTC: 30.83 )
Ranked among companies with meaningful Quick Ratio only.
BSTC' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 5.91 Max: 48.18
Current: 30.83
0.41
48.18
Days Sales Outstanding 62.45
BSTC's Days Sales Outstanding is ranked higher than
54% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. BSTC: 62.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSTC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.28  Med: 115.13 Max: 299.91
Current: 62.45
26.28
299.91

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
BSTC's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. BSTC: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSTC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -6  Med: -1.9 Max: 2.7
Current: -4.1
-6
2.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.54
BSTC's Price-to-Net-Cash is ranked lower than
52% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. BSTC: 6.54 )
Ranked among companies with meaningful Price-to-Net-Cash only.
BSTC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.85  Med: 13.14 Max: 133.33
Current: 6.54
2.85
133.33
Price-to-Net-Current-Asset-Value 5.70
BSTC's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. BSTC: 5.70 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BSTC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 7.06 Max: 40.52
Current: 5.7
1.05
40.52
Price-to-Tangible-Book 4.77
BSTC's Price-to-Tangible-Book is ranked lower than
53% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. BSTC: 4.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BSTC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.59  Med: 5.16 Max: 542.86
Current: 4.77
0.59
542.86
Price-to-Intrinsic-Value-Projected-FCF 1.88
BSTC's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.43 vs. BSTC: 1.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSTC' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 2.82 Max: 364.29
Current: 1.88
0.52
364.29
Price-to-Median-PS-Value 0.78
BSTC's Price-to-Median-PS-Value is ranked higher than
62% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. BSTC: 0.78 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSTC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.55 Max: 4.58
Current: 0.78
0.04
4.58
Price-to-Peter-Lynch-Fair-Value 1.08
BSTC's Price-to-Peter-Lynch-Fair-Value is ranked higher than
71% of the 65 Companies
in the Global Biotechnology industry.

( Industry Median: 1.79 vs. BSTC: 1.08 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSTC' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.61  Med: 1.2 Max: 2.67
Current: 1.08
0.61
2.67
Price-to-Graham-Number 2.39
BSTC's Price-to-Graham-Number is ranked higher than
51% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. BSTC: 2.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BSTC' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.87  Med: 2.81 Max: 9.41
Current: 2.39
0.87
9.41
Earnings Yield (Greenblatt) % 6.77
BSTC's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. BSTC: 6.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSTC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -22.5  Med: 3.3 Max: 7.7
Current: 6.77
-22.5
7.7
Forward Rate of Return (Yacktman) % 38.01
BSTC's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 132 Companies
in the Global Biotechnology industry.

( Industry Median: 13.13 vs. BSTC: 38.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSTC' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.6  Med: 0.2 Max: 39.2
Current: 38.01
-0.6
39.2

More Statistics

Revenue (TTM) (Mil) $27.36
EPS (TTM) $ 1.59
Beta2.19
Short Percentage of Float2.29%
52-Week Range $41.95 - 58.79
Shares Outstanding (Mil)7.19

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 28 29
EPS ($) 1.60 1.69
EPS without NRI ($) 1.60 1.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}